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Abstract
Background
In non-small cell lung cancer (NSCLC), PD-L1 expression on either tumor cells (TC) or both TC
and tumor-infiltrating immune cells (IC) is currently the most used biomarker in cancer immuno-
therapy. However, the mechanisms involved in PD-L1 regulation are not fully understood. To
provide better insight in these mechanisms, a multiangular analysis approach was used to
combine protein and mRNA expression with several clinicopathological characteristics.
Patients and methods
Archival tissues from 640 early stage, resected NSCLC patients were analyzed with immu-
nohistochemistry for expression of PD-L1 and CD8 infiltration. In addition, mutational status
and expression of a selection of immune genes involved in the PD-L1/PD-1 axis and T-cell
response was determined.
Results
Tumors with high PD-L1 expression on TC or on IC represent two subsets of NSCLC with
minimal overlap. We observed that PD-L1 expression on IC irrespective of expression on
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TC is a good marker for inflammation within tumors. In the tumors with the highest IC
expression and absent TC expression an association with reduced IFNγ downstream signal-
ing in tumor cells was observed.
Conclusions
These results show that PD-L1 expression on TC and IC are both independent hallmarks of
the inflamed phenotype in NSCLC, and TC-negative/IC-high tumors can also be categorized
as inflamed. The lack of correlation between PD-L1 TC and IC expression in this subgroup
may be caused by impaired IFNγ signaling in tumor cells. These findings may bring a better
understanding of the tumor-immune system interaction and the clinical relevance of PD-L1
expression on IC irrespective of PD-L1 expression on TC.
Introduction
One of the most studied tumor immune escape mechanisms is mediated through the inhibitory
programmed death-ligand 1 (PD-L1)/programmed death 1 (PD-1) pathway. The development of
anti-PD-L1/PD-1 monoclonal antibodies has led to long-lasting anti-tumor immune responses in a
subset of patients with non-small cell lung cancer (NSCLC). High PD-L1 expression as assessed by
immunohistochemistry (IHC) has consistently been reported to be associated with higher responses
to anti-PD-L1/PD-1 treatment, resulting in the development of various diagnostic PD-L1 IHC
assays [1–3]. The use of various diagnostic PD-L1 IHC assays has led to ambiguity as to how to use
this multi-faceted biomarker. In two randomized trials comparing the anti-PD-L1 antibody atezoli-
zumab to docetaxel in second line setting, PD-L1 expression on TC and on infiltrating immune
cells (IC) both appeared to be independently associated with response to atezolizumab [3, 4].
Besides PD-L1 expression, wider aspects of the tumor/immune-infiltrating complex are
under investigation as biomarkers for immunotherapy. Tumors can broadly be divided into
inflamed (hot) vs non-inflamed (cold) tumors. Typically, inflamed tumors show a pre-existing
antitumor immune response with abundance of tumor-infiltrating lymphocytes (TILs), IFNγ-
producing CD8+ T-cells and high expression of PD-L1. In contrast, non-inflamed tumors are
characterized as immune desert: containing hardly any TILs and rarely expressing PD-L1 [5,
6]. The development of gene expression profiling of tumors allows distinguishing ‘hot’ and
‘cold’ tumors by providing prognostic and predictive immune signatures; one example being
the T-effector (Teff) signature showing an association with efficacy in the randomized phase II
and III trials comparing atezolizumab to docetaxel [3, 4].
Hence, it is important to improve insights in the overlap and differences between PD-L1
expression on TC and/or IC and to relate this expression to other tumor features and markers
of the PD-L1/PD-1 axis and T-cell response. In order to do this, we used a multiangular
approach by combining protein and mRNA expression with clinicopathological characteris-
tics, including mutational analysis of well-known drivers of NSCLC in a large cohort of clini-
cally annotated resected NSCLC samples.
Material and methods
Sample collection and patient cohort
Inclusion criteria for this cohort were patients that had undergone a lung resection between
1990 and 2013 at one of four Dutch medical centers. Exclusion criteria were a synchronous
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primary tumor, unavailability of tumor tissue or patient follow-up data, histology of non-
NSCLC, e.g. SCLC or metastasized non-NSCLC. Clinical data about gender, smoking status,
neo-adjuvant and adjuvant treatment, age at resection, type of resection, tumor stage, progres-
sion free survival (PFS) and overall survival (OS) were collected. No data on treatment after
relapse of disease was available. The cohort included 768 samples with adequate patient and
tumor characteristics. For all these patients, formalin-fixed, paraffin-embedded (FFPE) tumor
samples were collected. After a second pathology revision, samples without sufficient vital
tumor material were excluded, leaving 640 samples eligible for further analysis. All tumors
were histopathologically classified according the 2015 WHO classification system [7]. TNM
classification was redefined for resections that were done before 2010 according to the 7th
lung cancer TNM classification and staging system. Smoking status was defined by pack years
(PY). Light smokers were defined by having less than 10 PY, including never smokers. Prior to
analysis the samples were de-identified. The Translational Research Board of the Netherlands
Cancer Institute-Antoni van Leeuwenhoek hospital approved the use of patient data and mate-
rial in this study.
Immunohistochemical staining, mutational and gene expression analysis
PD-L1 expression and CD8 staining was assessed in a central laboratory (HistoGeneX, Bel-
gium) using whole slide sections prepared from FFPE resection specimens. Sections were
stained using the rabbit anti-human anti-PD-L1 antibody (clone SP142, Spring Bioscience)
and the monoclonal mouse anti-human anti-CD8 antibody (clone C8/144B, DAKO) on a
Ventana BenchMark XT autostainer (Ventana Medical Systems). PD-L1 expression in TC was
assessed as the proportion of TC showing membrane staining of any intensity; expression in
IC was assessed as the proportion of tumor area occupied by PD-L1-positive IC of any inten-
sity (Figs 1A and 1B and S1) [3, 4]. In all specimens, total immune infiltrate and tumor cells
were assessed in the tumor area by a certified pathologist based on hematoxylin background
staining of the IHC slide and if needed based on the H&E staining. Positive and negative con-
trols were performed using tonsil tissue. The scoring algorithm was developed for the
approved VENTANA PD-L1 (SP142) Assay and further details concerning the PD-L1 staining
protocol have been described previously [8, 9]. PD-L1 score for expression on TC and IC was
available for 615 (96.1%) samples. CD8 staining was reported as the percent CD8-positive
tumor infiltrating immune cells in the tumor center, available for 615 (96.1%) samples.
Mutation analysis was performed using a microfluidics-based PCR platform running an
allele-specific multiplex test as previously described [10, 11]. The validated panel included a
total of 130 hot spot mutations (Table A in S1 File). Immunohistochemistry for ALK was per-
formed on a BenchMark Ultra autostainer (Ventana Medical Systems) using clone 5A4
(Abcam). For ALK FISH staining and analysis of the results was performed as described by the
manufacturer.
DNA was extracted using the Qiagen DNA mini kit (cat. No. 51306) and a minimum of
80ng DNA was shipped to Genentech Inc. for mutation analysis. Gene expression analysis was
performed using the NanoString nCounter Analysis system (NanoString) on 80-200ng RNA
extracted from FFPE tissue samples. A customized gene panel, including 795 targets including
multiple genes of immunologic function and cancer biology and including 4 housekeeping
genes was applied. Following thorough assay quality control, data were normalized and under-
went analysis. We report here results for CD8 (CD8A), PD-L1 (CD274), PD-1 (PDCD1),
PD-L2 (PDCD1LG2) and Teff signature that was defined as the mean expression for CD8A,
GZMA, GZMB, IFNG, EOMES, CXCL9, CXCL10 and TBX21 as previously described [3, 4].
The downstream IFNγ response signature was derived from the
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Fig 1. Examples of PD-L1 staining, scoring criteria, prevalence and overlap between PD-L1 expression on TC and IC and prevalence of
CD8 infiltration in the tumor center in NSCLC. (A) PD-L1 expression by IHC on both TC and IC for each subgroup. (B) PD-L1 IHC scoring
criteria on TC and IC (3) (C) Overall prevalence of overlapping PD-L1 subgroups. (D) Percentages in Venn diagrams represent the prevalence
of PD-L1 expression by TC and IC in overlapping subgroups. (E) Overall prevalence of CD8 infiltration in the tumor center.
https://doi.org/10.1371/journal.pone.0216864.g001
Absence of PD-L1 expression on tumor cells impaired IFNγ signaling in non-small cell lung cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0216864 May 24, 2019 4 / 13
DER_IFN_GAMMA_RESPONSE_UP gene set (MSigDB; http://software.broadinstitute.org/
gsea/msigdb; 71 genes), where signature expression was calculated by summing the log2-based
expression values for genes that are members of the gene set and that are present in the expres-
sion data (22 / 71 genes). To calculate the actual minus the expected (residual) IFNγ signature
expression, a linear model based on all samples was created describing the relationship
between downstream IFNγ response signature and Teff signature expression. This model was
used to calculate the expected IFNγ signature expression. Biomarker high and low subgroups
were defined by expression levels at or above various cut-offs, either above or below the
median or above or below the 25% or 75% quantile. Gene expression analysis was available for
530 (82.8%) of the samples.
Statistical analysis
All statistical tests were performed in R. Kaplan–Meier methodology was used to construct
survival curves. Stratified Cox regression models were used to estimate HRs and 95% CIs in
biomarker subgroup populations. For comparison of gene expression data among subgroups,
(pairwise) t-tests were performed. For comparison of protein expression data among sub-
groups, (pairwise) Wilcoxon rank sum tests were performed. For comparison of categorical
data among subgroups, Fisher’s exact tests or Pearson’s Chi-squared tests were used as indi-
cated. The false discovery rate (FDR) was controlled below 0.05 using Benjamini-Hochberg
method.
Results
Description of the cohort and distribution of PD-L1 protein expression and
CD8 infiltration
The cohort consisted of 640 NSCLC samples: 344 (53.8%) AC, 267 (41.8%) SCC and 29 (4.5%)
NSCLC NOS. Only 48 (7.5%) patients were light or never smokers. 83.9% of the cohort was
early stage disease (� stage II). Median follow-up time was 96.0 months (95% CI: 86–103). All
samples were screened for presence of an ALK translocation or mutations of well-known driv-
ers in NSCLC. Mutational analysis was available for 563 (88.0%) samples: 170 mutations were
found in 164 patients (29.1%). Six samples harbored two mutations. ALK IHC was available
for 630 (98.4%) samples. Four samples (0.6%) were ALK IHC positive and a translocation was
confirmed by FISH. EGFR, KRAS, BRAF and ALK aberrations were mutually exclusive.
Table 1 summarizes the clinicopathological characteristics and genetic alterations of our
patient cohort.
In order to investigate the overlap and differences of PD-L1 protein expression between TC
and IC, all samples were scored for PD-L1 expression on TC and on IC at all four expression
levels. Examples of PD-L1 staining, PD-L1 IHC scoring criteria, the overall prevalence and dis-
tribution by overlapping PD-L1 subgroups are presented in Figs 1A–1D and S1. Non-overlap-
ping PD-L1 subgroups are presented in S2 Fig. High PD-L1 expression (TC3 or IC3) was
present in 132 (21.5%) samples and 74 (12.0%) samples showed no PD-L1 expression (TC0
and IC0 subgroup) (Fig 1C). Only a minority of samples (10.4%) had CD8 infiltration in the
tumor center of 5% or higher (Fig 1E).
Inflammatory features like PD-L1 expression may be affected by traditional stratifying cri-
teria (i.e. gender, age, smoking status, histology, tumor stage or KRAS/EGFR status). In a uni-
variate analysis using the TC and IC scores separately a positive association between heavy
smoking and PD-L1 expression on TC (p = 0.016) was found, but not for PD-L1 expression on
IC. There was no significant difference in PD-L1 expression between the histologic subtypes
Absence of PD-L1 expression on tumor cells impaired IFNγ signaling in non-small cell lung cancer
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Table 1. Patients’ and tumor characteristics of the non-small cell lung cancer cohort.
AC SCC NSCLC NOS
Total (n = 640) 344 267 29
Gender
Male 163 (47.3%) 188 (70.4%) 17 (58.6%)
Female 181 (52.7%) 79 (29.6%) 12 (41.4%)
Median age at surgery (years, range) 62 (30–84) 67 (38–85) 57 (37–81)
Neo-adjuvant therapy 54 (15.7%) 13 (4.9%) 7 (24.1%)
Chemotherapy 21 (6.1%) 2 (0.7%) 1 (3.4%)
Concurrent chemo radiotherapy 8 (2.3%) 2 (0.7%) 4 (13.8%)
Sequential chemo radiotherapy 3 (0.9%) 0 0
Erlotinib [12] 22 (6.4%) 6 (2.2%) 2 (6.9%)
Radiotherapy 0 3 (1.1%) 0
No neo-adjuvant therapy 290 (84.3%) 254 (95.1%) 22 (75.9%)
Adjuvant treatment
Chemotherapy 49 (14.2%) 45 (16.9%) 8 (27.6%)
Radiotherapy 19 (5.5%) 24 (9.0%) 2 (6.9%)
Chemotherapy + radiotherapy 7 (2.0%) 9 (3.4%) 1 (3.4%)
No adjuvant therapy 244 (70.9%) 160 (59.9%) 14 (48.3%)
Unknown 25 (7.3%) 29 (10.9%) 4 (13.8%)
Smoking
Light smokers<10PY 42 (12.2%) 4 (1.5%) 2 (6.9%)
Heavy smokers�10PY 253 (73.5%) 224 (83.9%) 25 (86.2%)
Unknown 49 (14.2%) 39 (14.6%) 2 (6.9%)
Tumor stage at resection
Stage I 211 (61.3%) 131 (49.0%) 13 (44.8%)
Stage II 79 (23.0%) 95 (35.6%) 9 (31.0%)
Stage III 44 (12.8%) 34 (12.7%) 7 (24.1%)
Stage IV 10 (2.9%) 7 (2.6%) 0
Genetic alterations�
EGFR mutated 20 (6.3%) 1 (0.5%) 0
KRAS mutated 110 (34.6%) 7 (3.4%) 3 (10.3%)
ALK translocated 4 (1.3%) 0 0
PIK3CA mutated 10 (3.1%) 14 (6.8%) 0
BRAF mutated 1 (0.3%) 0 0
NRAS mutated 1 (0.3%) 2 (1.0%) 0
HRAS mutated 1 (0.3%) 0 0
No mutation detected 171 (53.8%) 182 (88.3%) 26 (89.7%)
Undetermined^ 26 61 0
Mean overall survival (months, range) 71 (0–285) 76 (0–289) 71 (6–273)
� percentages for analyzed samples only.
EGFR mutations included exon 19 deletions (n = 15), exon 20 insertions (n = 2) and exon 21 L858R mutations
(n = 4). No T790M mutations were found. KRAS mutations included mutations in codon 12 and 13 (n = 116) and
codon 61 (n = 4). Mutations in AKT1, ERBB2, FLT3, JAK2, KIT, MYD88 were not present within this cohort. All
present MET mutations (n = 30) were germline single nucleotide polymorphism (SNP).
^ mutation status was undetermined when no sufficient DNA was available or when the microfluidics-based PCR
platform lead to an invalid result.
SCC = squamous cell carcinoma, AC = adenocarcinoma, NSCLC NOS = non-small cell lung cancer not otherwise
specified, PY = pack years
https://doi.org/10.1371/journal.pone.0216864.t001
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(S3A–S3D Fig). PD-L1 expression on TC was significantly higher for KRAS mutant (KRASm)
tumors compared to KRAS wild type (KRASwt) tumors (p< 0.001) and this was irrespective
of smoking status. No difference was found for PD-L1 expression on IC by KRAS status (S3E
and S3F Fig). EGFRm status was not significantly associated with PD-L1 protein expression
(data not shown).
The correlation between PD-L1 protein expression and PD-L1 mRNA expression (encoded
by CD274) was investigated. Protein expression of both TC and IC was significantly associated
with mRNA expression of CD274 (S4 Fig).
Overlap and differences of PD-L1 protein expression on TC and IC
We then explored the distribution of PD-L1 expression and the overlap and differences
between expression on TC and IC. There was minimal overlap between TC3 and IC3 tumors
(1.0%, Fig 1D), which might suggest different mechanism of PD-L1 upregulation in tumor
cells compared to immune cells. Comparing TC3 tumors to IC3 tumors in regard to clinico-
pathological features did not reveal significant differences (Table B in S1 File). Next, we ana-
lyzed potential differences with respect to immunological features. To correct for potential
confounding of the true biology of TC3 and IC3 tumors by the PD-L1 expression in the other
compartment, we compared TC3 tumors based on various expression levels of IC (0 to 3) to
IC3 tumors based on various expression levels of TC (0 to 3) (Figs 2A–2C and S5). In the TC3
subgroup (n = 39), expression of all inflammatory markers showed a slight increase per
increasing IC subgroup except expression of CD274, but this was not significant. In the IC3
subgroup (n = 83), we found that only expression of CD274 increased per increasing TC score,
while the other inflammatory markers remained constant, i.e. CD8 infiltration, Teff signature,
CD8A, PDCD1 and PDCD1LG2 expression. Also, when evaluating TC0 samples based on vari-
ous levels of IC (0 to 3; n = 351) all inflammatory markers, including CD274, increased per
ascending IC subgroup. The IC score therefore seems to represent a characteristic of true ‘hot’
tumors.
As the TC0/IC123 subgroup (n = 286, 55.1%) contains the majority of samples in this
cohort (Fig 1D), we then sought to understand why tumors harboring an active immune infil-
trate showed no upregulation of PD-L1 on TC. Since IFNγ signaling is an important mecha-
nism for PD-L1 upregulation, we hypothesized that an impairment in downstream IFNγ
signaling within tumor cells might explain this phenomenon. It is expected that cytokine pro-
duction by an active immune infiltrate, represented by the Teff signature, will lead to down-
stream IFNγ signaling within tumor cells. Therefore, we determined the expression of selected
IFNγ target genes, and collectively represented them as an IFNγ response signature. The
expression of this IFNγ response signature was significantly lower in TC negative samples
compared to TC positive samples (p< 0.001, Fig 2D). As this difference was irrespective of the
expression of the IFNγ target PD-L1 on IC, this strongly suggests that expression of this IFNγ
response signature originated from tumor cells only and not the immune infiltrate. The Teff
and the IFNγ response signature showed a linear relationship (S6 Fig). We calculated the dif-
ference between the expected level of the IFNγ response signature based on this linear model
and the actual one (residuals). To overcome confounding by the IC score, again we compared
the residuals in TC0 tumors based on various subgroups of IC (0 to 3) (Fig 2E). In the TC0/
IC3 subgroup, we observed a significantly lower expression of IFNγ response as would be
expected by the linear model compared to the TC123/IC3 subgroup (p = 0.042). Expected
expression in the TC0/IC3 subgroup was lower compared to all other subgroups. This suggests
that the absence of PD-L1 expression on tumor cells in TC0/IC3 samples may be caused by
impaired IFNγ signaling in these tumor cells.
Absence of PD-L1 expression on tumor cells impaired IFNγ signaling in non-small cell lung cancer
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Fig 2. Associations of mRNA expression of CD274, infiltration of CD8 and the IFNγ response signature in non-overlapping PD-L1 expressing subgroups. (A)
Relative mRNA expression of CD274 and CD8 infiltration in TC3 tumors based on various levels of IC (n = 39). (B) Relative mRNA expression of CD274 and CD8
infiltration in IC3 tumors based on various levels of TC (n = 83). (C) Relative mRNA expression of CD274 and CD8 infiltration in TC0 tumors based on various levels of
IC (n = 351). (D) Relative mRNA expression of the IFNγ response signature in non-overlapping PD-L1 subgroups: TC0&IC0, TC0/IC123 and TC123/IC123 (n = 530). (E)
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Prognostic value of PD-L1 expression, CD8 infiltration and gene
expression
Recent data showed conflicting results concerning the prognostic value of PD-L1 expression
in NSCLC. After stratifying for tumor stage, we analyzed the prognostic value of several
inflammatory parameters measured in our cohort. PD-L1 protein expression -combined or on
TC/IC separately- and mRNA expression of CD274 had no effect on OS in our cohort (Fig
3A). CD8 infiltration by IHC only showed a trend towards improved OS, but CD8A transcript
levels were significantly associated with better OS (HR 0.72 (95%CI 0.55–0.95; p = 0.016, Fig
3B). High expression of the Teff signature (highest quartile) and PDCD1 (highest quartile) were
both positive prognostic markers (HR 0.68 (95%CI 0.49–0.96; p = 0.027), Fig 3C and HR 0.60
(95%CI 0.42–0.85; p = 0.0035), data not shown, respectively). Expression of PDCD1LG2 or the
IFNγ response signature had no OS relevance. Based on these results, we conclude that gene
expression profiling is a better indicator of prognosis than PD-L1 protein expression.
Discussion
To date, PD-L1 protein expression on tumor cells and on tumor infiltrating immune cells is
the most studied biomarker in cancer immunotherapy. This study sought to improve insights
in the relation of PD-L1 protein expression with traditional stratifying criteria, like histology
and oncogenic driver status, and other markers of the PD-L1/PD-1 axis and T-cell response.
In our cohort, the pattern of inflamed tumors was clearly established: expression of PD-L1
on either TC or IC, infiltration of CD8+ cells and mRNA expression of CD274, CD8A,
PDCD1, PDCD1LG2 and the Teff signature were all associated with one another. Besides this
overlap in inflamed features, also differences between PD-L1 expression on TC and IC were
found. Co-expression of PD-L1 at the highest level on both TC and IC rarely occurred: preva-
lence of TC3&IC3 population was only 1%. Fehrenbacher et al. also described this lack of over-
lap in advanced NSCLC and hypothesized an intrinsic mechanism of PD-L1 upregulation on
TC versus an adaptive mechanism on IC [3]. Unfortunately, as opposed to the studies in
advanced NSCLC, this early stage cohort contained very few TC123/IC0 samples (< 1%).
Therefore, our analyses had several limitations because of the risk of confounding by the
PD-L1 expression in the other compartment as we could not compare the true PD-L1 TC posi-
tive (TC123/IC0) to the true PD-L1 IC positive (TC0/IC123) tumors. By comparing IC3
tumors based on various levels of TC and TC3 as well as TC0 tumors based on various levels of
IC, we observed that inflammatory markers like CD8A and the Teff signature correlated most
clearly with the IC score. Not unsurprisingly, this was strongest within the TC0 subgroup and
shows that the IC score is a good measure for true ‘hot’ tumors.
By dividing our cohort into three non-overlapping subgroups -TC0&IC0, TC0/IC123 and
TC123/IC123- we were able to explore other differences between PD-L1 expression on TC vs
IC. We found a significantly lower IFNγ response signature expression in TC negative versus
TC positive tumors, suggesting an inability of the tumor cells to upregulate PD-L1 in the pres-
ence of an active and IFNγ producing immune infiltrate as is represented by expression of the
Teff signature. And as expected after performing further analysis between TC negative and TC
positive samples in increasing IC subgroups, strong evidence of a hampered IFNγ-PD-L1 axis
in tumor cells within the TC0/IC3 subgroup was found. As to our knowledge, this finding has
The actual minus the expected relative mRNA expression of the IFNγ response signature comparing TC negative to TC positive samples for each non-overlapping IC-
subgroup. Expected IFNγ response signature expression was obtained from the level of Teff signature expression based on their linear relationship. ns = non significant, �
p = 0.01–0.05, �� p< 0.01, ��� p< 0.001.
https://doi.org/10.1371/journal.pone.0216864.g002
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not been described or looked into before. We observed impaired expression of the majority of
the individual IFNγ response signature genes (data not shown), implying that the impaired
IFNγ signaling in TC0/IC3 tumors is due to alterations at an early level of the pathway: IFNGR
or JAK/STAT. Kowanetz et al. found that the TC0/IC3 subgroup had a response rate to the
PD-L1 inhibitor atezolizumab of 22%, which was higher than TC0&IC0 tumors (ORR 8%),
but lower compared to the TC3/IC0 subgroup (ORR 40%) [4, 13]. Therefore, it would be inter-
esting to investigate if restoring this impairment might improve the benefit on PD-1 blockade
in these patients.
For the PD-L1 staining, the SP142 antibody clone was used according to a validated proto-
col assessing PD-L1 expression on IC in addition to TC [3, 4]. This enabled a thorough assess-
ment of the differences and overlap between PD-L1 expression on TC versus IC. However, in
the Blueprint analysis comparing four PD-L1 IHC assays, the SP142 staining differed signifi-
cantly by producing a weaker staining on TC and fewer PD-L1 positive TCs compared to the
other three assays (22C3, 28–8 and SP263), which were similar in the analytical performance
[14]. Based on these differences between the assays it’s possible that some of the TC positive
tumors may have been unjustly qualified as a TC0 tumor in our cohort in comparison with
other PD-L1 assays. This may have resulted in an underestimation of the finding of a ham-
pered IFNγ-PD-L1 axis in our TC0 subgroup and might help explain why we did not find this
impairment in the TC0/IC2 or TC0/IC1 subgroup.
In conclusion, these results show the important contribution of PD-L1 expression on IC to
identify inflamed tumors. Impaired IFNγ response signaling in tumor cells may explain the
absence of PD-L1 expression on TC in the context of an activated immune infiltrate as repre-
sented by high PD-L1 IC positivity. These findings may help towards a better understanding
of the tumor-immune system interaction and also signify the clinical relevance of PD-L1
expression on IC as a biomarker for immunotherapy in NSCLC patients.
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